SYNGAP1 encephalopathy is a rare genetic disorder for which there is no treatment. It causes epilepsy, intellectual disability, psychomotor delay and, frequently, autism. It arises from mutations in ...

First Ascent Biomedical's Functional Precision Oncology bridges that gap by testing living tumor cells to generate actionable data in about 10 days, helping physicians choose the right treatment ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

They present a compelling story of radiation, mutation and survival against the odds. But the underlying science didn’t ...

SYNGAP1 encephalopathy is a rare genetic disorder for which there is no treatment, causing epilepsy, intellectual disability, psychomotor delay and, frequently, autism.

For decades, the standard explanation for autoimmune diseases like rheumatoid arthritis has rested on two pillars: inherited ...

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...

Artificial intelligence has the potential to transform cancer research, but its impact depends heavily on the quality, scale, ...

A large-scale genomic study published February 19 in Science has produced the first comprehensive map of the feline ...

Cancer cells are known for their “glutamine addiction,” but many can escape this weakness by switching to alternative fuels.

As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...

Of the nearly 77,000 Challengers sold in its debut year, just a handful were destined for export; this example is from a ...